We found that multiple CNVs, both gains and losses, affected EP300 and CBP in liver hepatocellular carcinoma (LIHC) and prostate adenocarcinoma (PRAD) (Fig. 5A and SI Appendix, Table S1) and correlated with their expression (SI Appendix, Fig. S7D). Here, CREBBP is linked to prostate adenocarcinoma.